Video, Portable and Carrier-Grade IP Phones from Grandstream Now Available for ISTRA by Enreach UCaaS Platform
23.2.2021 11:30:00 EET | Business Wire | Press release
Enreach, the fast-growing European unified communications group, has announced that multiple IP phones from Grandstream have been certified for use on its Unified Communications as a Service (UCaaS) platform, ISTRA by Enreach. Through Enreach for Service Providers, partners and their customers have immediate access to portable and video phones from Grandstream, plus carrier-grade devices designed for mass-deployment.
Bertrand Pourcelot, Managing Director at Enreach for Service Providers, said: “Grandstream’s name has become synonymous with IP phones that combine superior quality and ease-of-use, with options to suit a wide variety of budgets and requirements. Grandstream is a good fit for our portfolio of supporting products for the ISTRA by Enreach UCaaS platform, which is already used by approximately one million users via over 100 service providers in 20-plus countries.”
Grandstream IP phones certified for ISTRA by Enreach
Highlights of the ISTRA-certified range include Grandstream’s GXV3300 series of advanced IP video phones for Android, bringing multimedia AV communications to the desktop, with tablet-style functionality and web access.
For greater mobility in the workplace, the cordless WP810 and WP820 are portable WiFi IP phones, providing robust design and comprehensive features. As well as office or home-working environments, these phones are ideal for retail, logistics, medical, security and other vertical markets where portability is a benefit.
When large volumes of handsets are needed, the GRP2600 series of Carrier-Grade IP phones deliver powerful performance, simplicity of use and easy deployment. As well as supporting basic communications, these devices include next generation features for high-end users.
About ISTRA by Enreach
The ISTRA cloud based UCaaS platform is already deployed by over 100 service providers in more than 20 countries with approximately one million users. It is also the foundation for Enreach’s future-facing platform strategy across the entire group, as part of its ambition to be Europe’s UCaaS leader.
Enreach for Service Providers
Based in Sophia-Antipolis, France, Enreach for Service Providers (previously known as Centile Telecom Applications) is a European leader in the development of Cloud PBX and unified communications platforms for operators and integrators. As well as supporting Enreach for Service Providers own service provider customers, ISTRA by Enreach UCaaS platform is the foundation for Enreach’s future-facing strategy across the entire group, as part of its ambition to be Europe’s UCaaS leader. https://enreach.com/en/for-service-providers
About Enreach
Enreach is the parent company of various labels such as Voiceworks, Swyx, Eazit, i4IP, ipnordic, M Mobility, HeroBase, Network Telecom, Botsquad and masvoz. Enreach provides collaboration technology and telecoms services via their reselling and service providing partners or direct brands that are transformative for SMEs and the people that work with them. All brands contribute to intelligent, integrated IT and communication solutions that ensure optimal communication and workflow between organisations. Enreach’s mission is to give businesses access to the best communication and collaboration tools with an easy, user-centric interface built around their specific needs and systems. The group’s products put powerful features in reach of every business, no matter the industry or size, so their employees can focus on getting amazing things done. Enreach is active in the core markets Germany, the Netherlands, Denmark, UK, Spain and France with activities in 25 countries and 950 employees. https://enreach.com/
About Grandstream
Grandstream Networks, Inc. has been connecting the world since 2002 with SIP Unified Communications products and solutions that allow businesses to be more productive than ever before. Our award-winning solutions serve the small and medium business and enterprises markets and have been recognized throughout the world for their quality, reliability and innovation. Grandstream solutions lower communication costs increase security protection and enhance productivity. Their open standard SIP-based products offer broad interoperability throughout the industry, along with unrivaled features and flexibility. Visit www.grandstream.com for more information or connect with us on Facebook, LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005422/en/
Contact information
Media Contacts
Ambrose Communications
Maxine Ambrose
E mail: maxineambrose@ambrosecomms.com
Tel : + 44 7785 280930
Karine Merouze
International Marcoms Manager
Enreach for Service Providers
E-Mail: karine.merouze@enreach.com
Tel: +33 49 723 1265
For Grandstream
Phil Bowers
marketing@grandstream.com
Tel: 1-617-566-9300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom